In the media
February 16, 2022
On BBC Radio 5 Live, Owkin co-founder and CEO Thomas Clozel explains our new AI project to better detect HER2-positive breast cancer
Today our co-founder and CEO Thomas Clozel joined Naga Munchetty on B Radio to discuss our new project to develop hashtag#AI models to better detect HER2-positive breast cancer in women.
Share to:
About Owkin
Owkin is an AI company on a mission to solve the complexity of biology. It is building the first Biology Super Intelligence (BASI) by combining powerful biological large language models, multimodal patient data, and agentic software. At the heart of this system is Owkin K, an AI copilot and its new LLM finetuned on biology called Owkin Zero, used by researchers, clinicians, and drug developers to better understand biology, validate scientific hypotheses, and deliver better diagnostics and therapies faster.